)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Mallinckrodt (MNK) investor relations material
Mallinckrodt Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Completed merger of Mallinckrodt and Endo, creating a global, diversified therapeutics leader with expanded product diversity and capabilities; Endo results included post-July 31, 2025.
Divested Therakos business for $881.4M, using proceeds to reduce debt.
Announced Cristiano Stamolis as new President and CFO, bringing biotech, finance, and strategy expertise.
Integration plans underway, with synergy targets of at least $150M annual pretax run rate by year three and $75M in the first twelve months post-merger.
Progressing toward a planned spin-off of Par Health, the generics and sterile injectables business, targeted for Q4 2025.
Financial highlights
Legacy Endo Q2 2025 revenues were $448M, flat year-over-year; excluding divested International segment, revenues rose 2%.
Endo's adjusted EBITDA was $150M (down from $176M YoY); adjusted net income was $64M (down from $105M YoY), mainly due to lower gross margin and higher interest expense.
Legacy Mallinckrodt Q2 2025 net sales were $485M, down 5.7% YoY; excluding Therakos divestiture, net sales grew 8.5%. Net income improved to $2.4M from a $43M loss YoY.
Mallinckrodt adjusted EBITDA was $137M, down from $174M YoY, impacted by divestiture and increased competition.
Gross profit increased 18.9% to $231.8M; gross margin improved to 47.8% from 37.9%.
Outlook and guidance
Combined 2025 net sales expected between $3.57B and $3.62B; adjusted EBITDA between $1.1B and $1.13B.
Par Health 2025 net sales guided at $1.72B–$1.75B; adjusted EBITDA $450M–$470M.
Acthar Gel 2025 net sales guidance raised to 20–30% growth; XIAFLEX revenue growth reaffirmed in high single digits.
Plans to separate generics and sterile injectables businesses in Q4 2025, subject to board approval and conditions.
Expects continued integration and non-recurring costs related to the Endo deal and planned separation.
New corporate name and listing details
Endo's Sterile Injectables pipeline progress?
Why was Acthar Gel's 2025 guidance raised?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Mallinckrodt earnings date
Q3 20254 Nov, 2025
Next Mallinckrodt earnings date
Q3 20254 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Mallinckrodt plc is a specialty pharmaceutical company that focuses on developing, manufacturing, and commercializing treatments for autoimmune and rare diseases, as well as therapies for pain management and critical care. The company’s portfolio includes a range of branded and generic pharmaceuticals, with a strong emphasis on specialty therapies for conditions such as neurology, nephrology, rheumatology, and pulmonology. Mallinckrodt also offers imaging agents used in diagnostic procedures. Its products are primarily distributed to hospitals, physicians, and healthcare providers. The company is headquartered in Dublin, Ireland, and its shares are listed on the New York Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage